Vantage logo

Legend joins the billion-dollar club

With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.

Vantage logo

Covid-19 stalls biotech flotations

Several young drug developers managed to float in the first quarter, but new issues dried up in March when coronavirus infected the markets. Is the game back on?

Vantage logo

Storm clouds gather for biotech flotations

Only seven drug developers managed to float on Western exchanges in the third quarter, and new issues in October have struggled, with Biontech the latest example.